Wednesday, August 12, 2020

Crescita Therapeutics Inc - CTX.v

Crescita Therapeutics Inc - CTX.v owns a portfolio of non-prescription skincare products and has one FDA approved prescription product, Pliaglis. Crescita owns the sales and marketing rights in over 20 countries available for out-licensing.

On Aug 12, 2020 the company released Numbers

  • Revenue was $1,733, a decrease of $7,629. In Q2-F2019, the Company recognized $5,459 in up-front payments and guaranteed future minimum royalties in connection with the out-licensing agreement with Cantabria Labs ("Cantabria" and the "Cantabria Agreement");
  • Gross profit was $1,092, representing a gross margin of 63.0%;
  • Operating expenses (excluding COGS) were $2,318, a decrease of $1,012;
  • Recorded a non-cash impairment charge on intangible assets of $1,918 to reflect the projected impact of the pandemic-driven decrease in demand for certain products and services;
  • Adjusted EBITDA1 was $(781), a decrease of $5,864, mainly due to the revenue recognized in connection with the Cantabria Agreement in Q2-F2019 of $5,459;
  • Ending cash position was $9,265, a decrease of $69 versus Q1-F2020 and flat versus Q4-F2019.

Wednesday, August 5, 2020

Bluma Wellness Inc. - BWEL.U

Bluma Wellness Inc. - BWEL.U assembled one of the most experienced and talented teams in cannabis cultivation in the world. The talent made it clear that they were only willing to go on this journey to be the best, not the biggest.

The company's goal is a significant increase in the available premium cannabis product to sell to its customers after recent investment in cultivation and processing facilities in Florida. The company operates 4 stores with plans for 10 by the end of Q4. Production has gone from 300 pounds a month to 1,500 pounds a month.

On July 24, 2020 the company released News 

Bluma Wellness Inc. has agreed to issue 4,480,238 non-transferable common share purchase warrants to AFC Warehouse LLC (also known as Advanced Flower Capital) pursuant to the terms and conditions of the existing $15-million (U.S.) non-revolving, staged advance loan between Advanced Flower Capital and CannCure Investments Inc., a subsidiary of the company. The construction loan is being used, in part, to finance the expansion and completion of the company's facilities at the Indiantown greenhouse facility.